| NCT03949283 | III | Platinum resistant ovarian cancer | Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer | CA, FL, IN, LA, OH, OK, PA, WV | View Drugs | |
Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Docetaxel | Taxotere | Microtubule stabilizer/mitotic inhibitor | Approved in Other Cancers | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor | Approved in Ovarian Cancer |
|
|
| NCT04729387 | III | Platinum resistant or refractory high grade serous or endometrioid ovarian cancer without germ-line BRCA1/2 mutations | EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer | AZ, AR, CA, FL, IL, MD, MA, NY, OH, SD, TN, TX | View Drugs | View Results |
Alpelisib | PI3K inhibitor BYL719, BYL719, phosphoinositide 3-Kinase inhibitor BYL719, Piqray | PI3K alpha inhibitor | Approved in Other Cancers | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT05092360 | III | Platinum resistant or refractory ovarian cancer that must have had prior bevacizumab (5 or less prior therapies for platinum resistant disease) | A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7) | AZ, CA, FL, NJ, NY, NC, OH, OR, SC, SD, TX, VA | View Drugs | View Results |
Nemvaleukin alfa | intermediate-affinity interleukin-2 receptor agonist ALKS 4230, Nemvaleukin, ALKS4230 | IL-2/IL-15R beta and gamma agonist | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05116189 | III | Platinum resistant ovarian cancer; 1-2 prior systemic therapies | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65) | AZ, CA, CT, FL, GA, IL, IN, KY, LA, MD, MA, NJ, NY, NC, OH, OR, PA, SD, TN, TX, VA | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT05257408 | III | Platinum resistant high grade serous or high grade endometrioid ovarian cancer that must have had prior bevacizumab | A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA) | AZ, CA, GA, IL, KY, NM, OH, OR, SD, TX, VA, WI | View Drugs | View Results |
nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | NCCN Guidelines for Ovarian Cancer | Relacorilant | RELA, CORT125134 | GR antagonist | Clinical Trials |
|
|
| NCT05281471 | III | Platinum resistant or refractory ovarian cancer that must have had prior bevacizumab | A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Platinum-doublet Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076) | FL | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Cisplatin | CACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, Platosin | DNA damaging agent | Approved in Ovarian Cancer | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Olvimulogene nanivacirepvec | light-emitting oncolytic vaccinia virus GL-ONC1, GLV-1h68, GL-ONC1 | Induces immune response and tumor cell lysis | Clinical Trials |
|
|
| NCT05243524 | IIb | Platinum resistant ovarian cancer; all lesions must be less than 4 cm | Phase 2b Single Arm Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects With Platinum-Resistant, Epithelial Ovarian Cancer. | CA, FL, NY | View Drugs | View Results |
Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Maveropepimut-S | survivin antigen vaccine DPX-Survivac, DPX-Survivac | Immune response against cancer expressing survivin | Clinical Trials |
|
|
| NCT02312245 | II | Recurrent ovarian cancer | Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers | AZ, FL, MN | View Drugs | |
Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer | Topotecan | Hycamptamine, Hycamtin, TOPO | Topoisomerase I inhibitor | Approved in Ovarian Cancer |
|
|
| NCT02693535 | II | Ovarian expansion for CDKN2A loss or mutation or ERBB2/ERBB3 amplification, mutation or over-expression, or high TMB or Advanced solid tumors with molecular alterations in AKT1, ALK, ATM, ATR, BRAF, BRCA1/2, CDK4/6 AMP, CDK12, CDKN2A, CHEK2, CSF1R, FANCA, FGFR1/2/3, FLT3, KIT, MRE11A, MLH1, MSH2, MSH6, NBN, NRG1, NTRK1/2/3 AMP, PALB2, PDGFR, PDGFRB, PMS2, POLD1, POLE, RAF-1, RAD51C, RET, ROS1, TSC1/2, VEGFR, or with high MSI, high TMB, HRD+, or LOHhi | Targeted Agent and Profiling Utilization Registry (TAPUR) Study | AL, AZ, CA, CT, FL, GA, HI, IL, IN, ME, MI, NE, NH, NM, NY, NC, ND, OH, OR, PA, SC, SD, TN, TX, UT, VA, WA, WI | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers | Afatinib | BIBW 2992 MA2, Gilotrif, Afatinib dimaleate | EGFR, HER2, HER4 kinase inhibitor | Approved in Other Cancers | Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Crizotinib | c-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkori | c-Met and ALK kinase inhibitor | Approved in Other Cancers | Entrectinib | RXDX-101, TrkA/B/C/ROS1/ALK tyrosine kinase inhibitor RXDX-101, Rozlytrek | ALK, TRK, ROS1 kinase inhibitor | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Larotrectinib | Trk inhibitor LOXO-101, LOXO-101, Vitrakvi | pan-Trk kinase inhibitor | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Palbociclib | PD-0332991, PD0332991, Ibrance | CDK4/6 inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pertuzumab | Perjeta, monoclonal antibody 2C4, rhuMAb2C4 | HER2 dimerization inhibitor | Approved in Other Cancers | PHESGO | pertuzumab, trastuzumab, and hyaluronidase-zzxf | HER2 antagonist | Approved in Other Cancers | Regorafanib | BAY73-4506, multikinase inhibitor BAY 73-4506, Stivarga | Multi-targeted RTK inhibitor | Approved in Other Cancers | Sunitinib | Sutent, Sunitinib malate | VEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibit | Approved in Other Cancers | Talazoparib | MDV3800, BMN-673, Talazoparib Tosylate, Talzenna | PARP inhibitor | Approved in Other Cancers | Temsirolimus | Torisel, CCI-779 | mTOR inhibitor | Approved in Other Cancers | Trastuzumab | Herceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal Antibody | HER2 antagonist | Approved in Other Cancers | Tucatinib | Irbinitinib, ONT-380 | HER2 kinase inhibitor | Approved in Other Cancers |
|
|
| NCT02628067 | II | Advanced solid tumors with high MSI or high TMB | A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) | CA, MA, NJ | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT02873962 | II | Partially platinum sensitive or resistant ovarian cancer (for combo w/ rucaparib patients cannot be BRCA1/2 mutated) | A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | MA | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Rucaparib | AG-014699, PF 01367338, CO-338, Rubraca | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT01851369 | II | Granulosa cell ovarian cancer | A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas | MD | View Drugs | View Results |
Methoxyamine | TRC102 | Base excision repair inhibitor | Clinical Trials | Temozolomide | Temodal, Temodar, Methazolastone | DNA damaging agent | Approved in Other Cancers |
|
|
| NCT02364713 | II | Platinum resistant, refractory or persistent ovarian cancer (no measurable disease outside the peritoneal cavity) | MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer | AZ, FL, MN | View Drugs | View Results |
MV-NIS | oncolytic measles virus encoding thyroidal sodium iodide symporter | Induces immune response and tumor cell lysis | Clinical Trials |
|
|
| NCT02675829 | II | Advanced solid tumors with HER2 amplification | A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers | NJ, NY | View Drugs | View Results |
Trastuzumab emtansine | trastuzumab-MCC-DM1 immunoconjugate, trastuzumab-MCC-DM1 antibody-drug conjugate, trastuzumab-MCC-DM1, trastuzumab-DM1, T-DM1, Kadcyla, ado trastuzumab emtansine | ADC: anti-HER2 + microtubule destabilizer (DM1) | Approved in Other Cancers |
|
|
| NCT02834013 | II | Advanced ovarian small cell cancer; hypercalcemic type | DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors | AL, AK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WY | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03026062 | II | Platinum resistant or refractory clear cell ovarian cancer or mixed epithelial carcinoma with a clear cell component | Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer | TX | View Drugs | |
Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Tremelimumab | Ticilimumab, CP-675206, CP-675,206, CP-675, anti-CTLA4 human monoclonal antibody CP-675,206 | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03212274 | II | Advanced solid tumors with IDH1 or IDH2 mutations | A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors | CA, CT, FL, KS, MD, MA, MO, NH, NJ, NY, NC, OH, OK, PA, TN, TX, WI | View Drugs | |
|
|
| NCT03310879 | II | Advanced solid tumors with CCND1/2/3 alterations or CDK4/6 amplifications | A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6 | MA | View Drugs | View Results |
Abemaciclib | Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT03355976 | II | Recurrent clear cell ovarian cancer | BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | IL, RI | View Drugs | View Results |
Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03412877 | II | Advanced solid tumors | A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in Patients With Metastatic Cancer | MD | View Drugs | View Results |
Aldesleukin | | IL-2 receptor agonist | Approved in Other Cancers | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | Individual Patient TCR-Transduced PBL | autologous PBLs retrovirally-transduced with TCRs targeting neoantigens | Immune response against neoantigens | Clinical Trials | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03428802 | II | Advanced solid tumors with high MSI and with POLE, POLD, or BRCA1/2 mutations | A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability | NJ, NY | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03682289 | II | Advanced solid tumors with ARID1A or ATM alterations | Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies | CA | View Drugs | View Results |
Ceralasertib | ATR kinase inhibitor AZD6738, AZD6738 | ATR kinase inhibitor | Clinical Trials | Olaparib | Lynparza, AZD2281 | PARP inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03693014 | II | Advanced solid tumors with dMMR, high TMB or high MSI with limited progression on checkpoint inhibitor treatment | A Phase II Trial of Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade | CT, NJ, NY, PA | View Drugs | View Results |
Atezolizumab | Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446 | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Ipilimumab | Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers | Nivolumab | BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Radiation Therapy | Irradiation, Radiotherapy | | |
|
|
| NCT03574779 | II | Platinum resistant ovarian cancer or Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant) | A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments And/Or Combinations of Treatments in Participants With Ovarian Cancer (OPAL) | CA, IL, ME, MA, MN, OK, SD | View Drugs | View Results |
Bevacizumab | immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin | VEGF antagonist | Approved in Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Dostarlimab | TSR-042, anti-PD-1 monoclonal antibody TSR-042, ANB011 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Niraparib | Zejula, MK4827 | PARP inhibitor | Approved in Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03732950 | II | Recurrent ovarian cancer | A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling | CA, MN | View Drugs | View Results |
Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03673124 | II | Recurrent low grade serous ovarian cancer | A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum | CA, FL, GA, IL, IN, MI, MN, NH, NJ, NM, OH, OK, PA, RI, TX | View Drugs | View Results |
Letrozole | Femara | Aromatase inhibitor | NCCN Guidelines for Ovarian Cancer | Ribociclib | Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali | CDK4/6 inhibitor | Approved in Other Cancers |
|
|
| NCT03742895 | II | Advanced solid tumors without BRCA1/2 mutations, with Homologous Recombination Repair gene mutations (e.g., ATM, PALB2, RAD51D) or HRD+ | A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer | MD, NE, NJ, NY, SD, WA | View Drugs | View Results |
|
|
| NCT03878849 | II | Recurrent ovarian cancer | Phase II, Prospective Open Label, Single Arm Study to Investigate Anti-tumor Effect and Tolerability of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRPĀ® | OK | View Drugs | View Results |
Stenoparib | PARP/Tankyrase inhibitor 2X-121, E7449, 2X-121 | PARP inhibitor | Clinical Trials |
|
|
| NCT01174121 | II | Advanced solid tumors | A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab | MD | View Drugs | View Results |
Aldesleukin | | IL-2 receptor agonist | Approved in Other Cancers | Cyclophosphamide | Sendoxan, Procytox, Ledoxina, Genoxal, Fosfaseron, Enduxan, Endoxana, Endoxan, Cytophosphan, Cyclostine, Cyclostin, CYCLO-cell, Cycloblastine, Cycloblastin, Cicloxal, Carloxan, Neosar, Cytoxan, Clafen, Zytoxan, Syklofosfamid, Mitoxan, Cytophosphane, Cyclophosphanum, Cyclophosphan, Cyclophosphamidum, Cyclophosphamid monohydrate, Cyclophospham, CPM, CP monohydrate, Claphene, Ciclofosfamide, Ciclofosfamida | DNA damaging agent | Approved in Ovarian Cancer | Fludarabine | Fludara Oral, 2-F-ara-AMP, Beneflur | DNA synthesis inhibitor | Approved in Other Cancers | Pembrolizumab | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 | Blocks PD-L1/2 inhibition of T cells | Approved in Other Cancers | Selected Young TIL | | Immune response against tumor-associated antigens | Clinical Trials |
|
|
| NCT03911557 | II | Advanced solid tumors with moderate/high TMB | Phase 2 Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors | KY | View Drugs | View Results |
Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Tremelimumab | Ticilimumab, CP-675206, CP-675,206, CP-675, anti-CTLA4 human monoclonal antibody CP-675,206 | Blocks CTLA-4 inhibition of T cells | Approved in Other Cancers |
|
|
| NCT03907475 | II | Advanced solid tumors (with tumor amenable to skin biopsy) | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors | MD | View Drugs | View Results |
Capecitabine | Xeloda, CAPE | RNA processing and thymidylate synthase inhibitor | NCCN Guidelines for Ovarian Cancer | Carboplatin | Paraplatin, Novoplatinum | DNA damaging agent | Approved in Ovarian Cancer | Durvalumab | Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi | Blocks PD-L1 inhibition of T cells | Approved in Other Cancers | Gemcitabine | Gemzar | Ribonucleotide reductase and DNA synthesis inhibitor | Approved in Ovarian Cancer | Liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, Doxil | Topoisomerase II inhibitor | Approved in Ovarian Cancer | nab-Paclitaxel | Paclitaxel Albumin-Stabilized Nanoparticle Formula, Abraxane, ABI-007 | Microtubule stabilizer/mitotic inhibitor | NCCN Guidelines for Ovarian Cancer | Paclitaxel | Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL | Microtubule stabilizer/mitotic inhibitor | Approved in Ovarian Cancer |
|
|
| NCT03935893 | II | Advanced solid tumors | A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced S |